Drug Approval | October 02, 2024
Aurobindo Pharma receives USFDA approval for Cephalexin Tablets
The product is expected to be launched in Q3FY25
The product is expected to be launched in Q3FY25
Lupin's Pithampur Unit-1 gets Form 483 from USFDA with 3 observations
Agreement enables access of EU-approved treatment for myotonia symptoms in non-dystrophic myotonic disorders to patients from Argentina and Colombia
Developed in consultation with clinicians and patients for an enhanced user experience
India has taken the lead in recognising NAFLD as a major non-communicable disease
India called for stronger investments in health and social equity at G20 Joint Finance-Health Task Force Meeting
Showcases specialty and sustainable materials for healthcare at Medtec China 2024
Global survey reveals top workforce concerns, evolving strategic priorities, and key technology investment areas for life sciences manufacturers
At 24 months, data from the Phase 1 exPDite trial continue to show a favorable safety profile in all 12 participants in the trial’s high and low dose cohorts
She reiterated the nation's commitment to eliminating TB as a public health problem by 2030 and ensuring a healthier future for all
Subscribe To Our Newsletter & Stay Updated
